Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& classes

: Dissociative

or targets protofibrils

Use the filters below to narrow your results.

Leqembi (1) · Spravato (1)

None (2)

Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

10 mg/kg IV every 2 weeks (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 28 mg/device (each dose uses 2 devices) (1)

10 mg/kg q2w (1) · 84 mg per session (1)

Intranasal (under direct medical supervision) (1) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1)

Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1) · Within hours of first administration (1)

Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Ongoing dosing (1)

~5-7 days (1) · ~7-12 hours (1)

100% (IV) (1) · ~48% intranasal (1)

Avoid; may cause fetal harm (1) · Limited data (1)

Rx, Schedule III (US). REMS program required. (1) · Rx; REMS-like program for ARIA monitoring (1)

Showing below up to 2 results in range #1 to #2.

E

Esketamine

L

Lecanemab

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"